Kalocyte, Inc.

kalocyte, inc. is developing a freeze-dried blood substitute that could be reconstituted and administered to treat traumatic hemorrhage when banked blood is unavailable (ambulances, military environments, developing world) or undesirable (cardiac surgery and organ perfusion). kalocyte’s erythromer™ red cell substitute is human hemoglobin encapsulated in a synthetic polymer shell. its design precisely emulates red blood cell oxygen binding/release. the shell does not require donor cross-matching. the nanoparticle has prolonged lyophilized stability at room temperature, is transportable in simple packaging, and is amenable to facile reconstitution with water for immediate field administration. the product will not require refrigeration and can be carried by soldiers and medics for prolonged field care. the prototype has passed rigorous initial ‘proof of concept’ testing in rodent animal models of hemorrhage and hypoxemia. these results led to $4.9m in nih and dod grant awards that will e